Lewis, Basil S.

Dabigatran versus warfarin in patients with atrial fibrillation

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 11,215

Apixaban versus warfarin in patients with atrial fibrillation

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 8,943

2023 ESC Guidelines for the management of acute coronary syndromes

Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 5,333

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 5,051

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 4,487

Apixaban in patients with atrial fibrillation

Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 2,483

Rivaroxaban with or without aspirin in stable cardiovascular disease

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 2,438

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,642

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 848

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthPeripheral Artery Disease Management

Cited by 766

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 725

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 603

Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes

Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van `t Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., et al. (2009) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 506

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 255

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

Attaei, M. W., Khatib, R., McKee, M., Lear, S., Dagenais, G., Igumbor, E. U., AlHabib, K. F., Kaur, M., Kruger, L., Teo, K., et al. (2017) · The Lancet Public Health

Blood Pressure and Hypertension StudiesPharmaceutical Economics and Policy

Cited by 209

Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal

Inflammatory mediators and NSAID effectsAntiplatelet Therapy and Cardiovascular Diseases

Cited by 164

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 158

An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial

Bergmark, B. A., O’Donoghue, M. L., Murphy, S. A., Kuder, J. F., Ezhov, M. V., Ceška, R., Gouni-Berthold, I., Jensen, H. K., Tokgozoglu, S. L., Mach, F., et al. (2020) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthCardiac Valve Diseases and Treatments

Cited by 137

Brachial artery endothelial function in residents and fellows working night shifts

Amir, O., Alroy, S., Schliamser, J. E., Asmir, I., Shiran, A., Flugelman, M. Y., Halon, D. A., & Lewis, B. S. (2004) · The American Journal of Cardiology

Sleep and Work-Related FatigueCardiovascular Health and Disease Prevention

Cited by 92

Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells

Preis, M., Schneiderman, J., Koren, B., Ben-Yosef, Y., Levin-Ashkenazi, D., Shapiro, S., Cohen, T., Blich, M., Israeli-Amit, M., Sarnatzki, Y., et al. (2016) · Gene Therapy

Tissue Engineering and Regenerative MedicineAngiogenesis and VEGF in Cancer

Cited by 13

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial

Kang, Y. M., Giugliano, R. P., Ran, X., Deedwania, P., De Ferrari, G. M., George, J. T., Gouni-Berthold, I., Paiva da Silva Lima, G., Handelsman, Y., Lewis, B. S., et al. (2025) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9